Editorial on this Article from Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-05-16 收录
数据链接：
官方服务：
资源简介：
Editorial on this Article from Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
创建时间：
2009-06-15
